Aytu BioPharma Statistics
Total Valuation
Aytu BioPharma has a market cap or net worth of $23.18 million. The enterprise value is $19.41 million.
| Market Cap | 23.18M |
| Enterprise Value | 19.41M |
Important Dates
The last earnings date was Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aytu BioPharma has 10.73 million shares outstanding. The number of shares has increased by 16.94% in one year.
| Current Share Class | 10.73M |
| Shares Outstanding | 10.73M |
| Shares Change (YoY) | +16.94% |
| Shares Change (QoQ) | +4.74% |
| Owned by Insiders (%) | 5.63% |
| Owned by Institutions (%) | 18.09% |
| Float | 7.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.41 |
| Forward PS | 0.36 |
| PB Ratio | 0.66 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.10 |
| P/OCF Ratio | 13.82 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 11.80 |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.65.
| Current Ratio | 1.12 |
| Quick Ratio | 0.85 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | n/a |
| Debt / FCF | 13.95 |
| Interest Coverage | -3.08 |
Financial Efficiency
Return on equity (ROE) is -97.42% and return on invested capital (ROIC) is -36.65%.
| Return on Equity (ROE) | -97.42% |
| Return on Assets (ROA) | -3.66% |
| Return on Invested Capital (ROIC) | -36.65% |
| Return on Capital Employed (ROCE) | -13.34% |
| Weighted Average Cost of Capital (WACC) | 6.65% |
| Revenue Per Employee | $681,916 |
| Profits Per Employee | -$410,301 |
| Employee Count | 83 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 2.15 |
Taxes
In the past 12 months, Aytu BioPharma has paid $447,000 in taxes.
| Income Tax | 447,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.42% in the last 52 weeks. The beta is 0.24, so Aytu BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -4.42% |
| 50-Day Moving Average | 2.29 |
| 200-Day Moving Average | 2.37 |
| Relative Strength Index (RSI) | 45.37 |
| Average Volume (20 Days) | 25,528 |
Short Selling Information
The latest short interest is 354,360, so 3.30% of the outstanding shares have been sold short.
| Short Interest | 354,360 |
| Short Previous Month | 407,982 |
| Short % of Shares Out | 3.30% |
| Short % of Float | 4.64% |
| Short Ratio (days to cover) | 8.96 |
Income Statement
In the last 12 months, Aytu BioPharma had revenue of $56.60 million and -$34.06 million in losses. Loss per share was -$3.71.
| Revenue | 56.60M |
| Gross Profit | 36.66M |
| Operating Income | -6.90M |
| Pretax Income | -33.67M |
| Net Income | -34.06M |
| EBITDA | -2.63M |
| EBIT | -6.90M |
| Loss Per Share | -$3.71 |
Balance Sheet
The company has $26.72 million in cash and $22.94 million in debt, with a net cash position of $3.78 million or $0.35 per share.
| Cash & Cash Equivalents | 26.72M |
| Total Debt | 22.94M |
| Net Cash | 3.78M |
| Net Cash Per Share | $0.35 |
| Equity (Book Value) | 35.14M |
| Book Value Per Share | 3.27 |
| Working Capital | 7.35M |
Cash Flow
In the last 12 months, operating cash flow was $1.68 million and capital expenditures -$34,000, giving a free cash flow of $1.64 million.
| Operating Cash Flow | 1.68M |
| Capital Expenditures | -34,000 |
| Depreciation & Amortization | 4.27M |
| Net Borrowing | 383,000 |
| Free Cash Flow | 1.64M |
| FCF Per Share | $0.15 |
Margins
Gross margin is 64.78%, with operating and profit margins of -12.19% and -60.17%.
| Gross Margin | 64.78% |
| Operating Margin | -12.19% |
| Pretax Margin | -59.49% |
| Profit Margin | -60.17% |
| EBITDA Margin | -4.64% |
| EBIT Margin | -12.19% |
| FCF Margin | 2.90% |
Dividends & Yields
Aytu BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.94% |
| Shareholder Yield | -16.94% |
| Earnings Yield | -146.89% |
| FCF Yield | 7.09% |
Analyst Forecast
The average price target for Aytu BioPharma is $9.50, which is 339.82% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.50 |
| Price Target Difference | 339.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 12.49% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 6, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 6, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Aytu BioPharma has an Altman Z-Score of -3.82 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.82 |
| Piotroski F-Score | 3 |